Work

Development of a Scalable Synthesis of Casdatifan (AB521), a Potent, Selective, Clinical-Stage Inhibitor of HIF-2α

Year: 2025

Type: article

Source: Organic Process Research & Development

DOI: 10.1021/acs.oprd.4c00497

Authors: Clayton Hardman, Artur K. Mailyan, Guillaume Mata, Joel W. Beatty, Samuel L. Drew, Jeremy Fournier, Jaroslaw Kalisiak, Brandon R. Rosen, Matthew Epplin, Balint Gal, Kai Yu, Zhang Wang, Karl Haelsig, Anh Tran, Manmohan R. Leleti, Jay P. Powers, Kenneth V. Lawson

Institution: Arcus Biosciences (United States)

Language: English

Topic: Asymmetric Synthesis and Catalysis

Subfield: Organic Chemistry

Field: Chemistry

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407154651

FWCI: 1.744

Cites: 39

Cited by: 6

Related to: 10